Oncologists have a shopping CAR-T full of complaints, with safety questions for cell therapies No. 1
CAR-T cell therapies have boomed in the past few years since the first FDA approval of this revolutionary new way of treating blood cancer back in 2017, but, while the technology has sped through, ...
CAR-T treatment generally involves extracting disease-fighting white blood cells known as T-cells from a patient, re-engineering them to attack cancer and infusing them back into the body. Novartis, ...
The US Food and Drug Administration has launched an investigation into certain treatments for cancer and whether these therapies themselves may be associated with the risk of developing secondary ...
This week’s episode of “The Top Line,” is the final part of a three-part series diving into the latest advancements in cell and gene therapy manufacturing. In this episode, Fierce Pharma’s Fraiser ...
The Food and Drug Administration is requesting that CAR-T cell therapies now come with a Boxed Warning about secondary malignancies that have been reported in patients who undergo these treatments.
The U.S. Food and Drug Administration has told drugmakers to add a boxed warning to a type of cancer treatment called CAR-T therapy, saying the treatment itself may sometimes cause a secondary cancer.
Dublin, June 20, 2019 (GLOBE NEWSWIRE) -- The "NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034" drug pipelines has been added to ResearchAndMarkets.com's offering. Diffuse ...
The U.S. Food & Drug Administration (FDA) recently removed its Risk Evaluation and Mitigation Strategies (REMS) designation from CAR T immunotherapies. REMS is occasionally applied to drugs with ...
The US Food and Drug Administration (FDA) on Wednesday approved the first gene therapy, Novartis' Kymriah (tisagenlecleucel) for certain pediatric and young adult patients with a form of acute ...
ZURICH (Reuters) - Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval ...
(Reuters) -The U.S. health regulator on Monday asked a host of drugmakers, including Gilead Sciences, Johnson & Johnson and Novartis, to add a serious warning on the label of their cancer therapies ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results